Long-Term Care Updates
|
|
- Neil Harrell
- 5 years ago
- Views:
Transcription
1 Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey reported that 12.8% of HAIs are caused by infections (CDI). 1 The previous clinical practice guidelines for CDI treatment were published in Since this publication, many studies have examined therapeutic regimens used in the treatment of CDI. On February 15, 2018 the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) released updated guidelines addressing changes in diagnosis and treatment of CDI. The updates this newsletter will discuss include changes to first-line antibiotic therapy, fecal microbiota transplantation, a new monoclonal antibody therapy, and various additional recommendations related to CDI treatment. 4 Recent information related to CDI therapy not addressed in the guidelines, including a new vancomycin oral solution and a fidaxomicin extended-pulsed dosing regimen, will also be reviewed. One major update to the CDI guidelines is a change in the recommendations for first-line treatment. Metronidazole was previously preferred as first-line for mild-to-moderate infections. The previous recommendation was based on studies such as a 2007 randomized, controlled trial by Zar et al, which found no statistical difference between vancomycin and metronidazole for mild CDI. 5 In the years since this study was released, more evidence has been published justifying a shift away from metronidazole for patients with mild or moderate infection. In a retrospective cohort study by Siegfried et al and two randomized, controlled trials by Johnson et al, investigators assessed treatment response to initial therapy and rate of CDI recurrence in a total of 1,286 patients. 6,7 In the study by Siegfried et al, which included patients with mild-to-moderate CDI, treatment response was 97% for vancomycin compared to 82% for metronidazole (p=0.002). These data suggest for every 7 patients treated with vancomycin instead of metronidazole, one additional patient will experience clinical success, or a resolution of diarrhea and absence of severe abdominal discomfort due to CDI for more than 2 consecutive days. The recurrence rate following vancomycin treatment was 13% compared to 9% for metronidazole, though this difference was not significant (p=0.44). It is important to note that this study does not address the power required to detect a difference in recurrence rates. 6
2 A combined analysis of the studies by Johnson et al included patients with 3 or more bowel movements per day with loose consistency, a positive toxin assay result, or pseudomembrane on endoscopy, and no other likely cause of diarrhea. In these studies, metronidazole-treated patients had a response rate of 72.7%, which was inferior to the 81.1% response rate seen with vancomycin for patients of all disease severities (p=0.02). These studies showed that for every 12 patients treated with vancomycin instead of metronidazole, 1 additional treatment response will be seen. Patients also had greater clinical success taking vancomycin for their first occurrence of CDI, compared to metronidazole (82.7% vs. 75%; p= 0.04; NNT=13). When the combined study data was analyzed by disease severity, the investigators found no significant difference in rates of clinical success for mild, moderate, or severe CDI infection. The differences in recurrence rates were insignificant between the three subgroups, as well. Rates of CDI recurrence were similar between the two groups containing all severities of disease. 7 These two larger studies were each powered to detect a statistical difference in recurrence rates. The IDSA/SHEA guidelines do not provide clear recommendations on categorizing the severity of CDI, meaning studies such as these that discuss disease severity often use their own criteria for categorizing patients. The updated guidelines cite this evidence, among additional studies, as justification for the preference for vancomycin or fidaxomicin over metronidazole for all severities of CDI infections. The table below summarizes current therapy recommendations (see Table 1 on the next page). 4 The 2018 guideline updates recognize the approval of bezlotoxumab for adjunctive treatment in patients at high risk of CDI recurrence. This monoclonal antibody binds to toxin B and neutralizes it, preventing its toxic effects. 10 In two double-blind, randomized, placebo-controlled trials by Wilcox et al, bezlotoxumab showed significantly lower rates of CDI recurrence compared to placebo (16-17% recurrence vs 28%, p 0.001). Fecal Transplantation The updated guidelines also address the role of fecal transplantation in CDI. Candidates who could be considered for this therapy include patients with multiple recurrences of who have failed multiple antibiotic treatments. 4 In a systematic review by Wang et al, adverse events of fecal transplantation seemed to most often be self-limited. Commonly reported side effects included abdominal discomfort, diarrhea, transient fever, nausea, vomiting, and constipation. 8 Additional recommendations from investigators include an "induction course" of 3 to 4 days of vancomycin before the transplantation. 4 Potential donor candidates for this procedure include those who have been cleared as non-infectious through blood and fecal tests. Donor exclusion criteria include those who have received antibiotics in the last 3 months, preexisting chronic conditions, malignant diseases, chronic infections, autoimmune diseases, or patients taking immunosuppressive agents. 9
3 Table 1. Therapy Recommendations in the 2018 Update 4 Clinical Definition Initial episode, non-severe Initial episode, severe First recurrence Recommended Treatments Vancomycin 125 mg orally, 4 times daily for 10 days OR Fidaxomicin 200 mg orally, 2 times daily for 10 days OR Alternate regimen if other agents are not available: metronidazole 500mg orally, 3 times daily for 10 days Vancomycin 125 mg orally, 4 times daily for 10 days OR Fidaxomicin 200 mg orally, 2 times daily for 10 days Vancomycin 125 mg orally, 4 times daily for 10 days if metronidazole was used for 1st episode OR Use a prolonged tapered and pulsed vancomycin regimen if standard regimen was used OR Fidaxomicin 200 mg orally, twice daily for 10 days if vancomycin was used for 1st episode Second or subsequent recurrence Vancomycin tapered and pulsed regimen OR Vancomycin normal regimen followed by rifaximin 400 mg orally, 3 times daily for 20 days OR Fidaxomicin 200 mg orally, 2 times daily for 10 days OR Fecal microbiota transplantation Data from these studies suggest that for every 9 to 10 patients treated with bezlotoxumab, 1 CDI recurrence will be prevented compared to placebo. 11 As more studies are published comparing this agent to other therapies for recurrent CDI, future guideline updates will most likely address the role of bezlotoxumab in treatment. Though not mentioned in the guidelines, an important update to CDI therapy includes the approval of an oral vancomycin liquid, marketed as Firvanq. This reconstituted product will replace CutisPharma's currently available vancomycin compounding kit. The drug is expected to launch April 2nd, Table 2 on the next page provides important information regarding Firvanq dosing and administration considerations.
4 Table 2. Characterisitics of Firvanq TM (oral vancomycin hydrochloride solution) 13 Indications Adult Dosing for CDAD Adverse Reactions Geriatric Considerations Preparation Concentrations C. difficile-associated diarrhea (CDAD) Enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) 125 mg orally 4 times daily for 10 days Adverse events are similar, but not identical, to other oral vancomycin products. Most common ( 10%): nausea (17%), abdominal pain (15%), and hypokalemia (13%) Renal function should be monitored during and after treatment due to possibility of systemic absorption. Geriatric patients may take longer to respond to therapy than younger adults. Each kit contains 1 bottle of vancomycin hydrochloride USP powder and 1 bottle of premeasured grape-flavored diluent. Vancomycin oral solution is available in a 25 mg/ml or 50 mg/ml concentrations Contraindications Storage Known hypersensitivity to vancomycin Refrigeration (36 to 46 F) An additional item not addressed in the updated CDI guidelines, due to date of publication, includes the potential for improved efficacy of fidaxomicin with extended-pulsed dosing. A recent randomized, controlled, open-label trial by Guery et al administered fidaxomicin 200 mg tablets orally twice daily on days 1-5 (pulsed dosing) and once daily on alternate days for days 7-25 (extended dosing). 14 This regimen was compared to standard vancomycin dosing. The hypothetical justification behind this dosing regimen is the probable gut microbiota-sparing benefits of maintaining lower concentrations combined with longer therapy duration. Before this study, evidence of improved outcomes in extended-pulsed dosing had only been addressed in case series. The primary endpoint of this study was sustained clinical cure 30 days after stopping treatment which was assessed in 364 patients, all of whom were 60 years and older. Fidaxomicin resulted in clinical cure in 70% of patients, compared to 59% of patients taking vancomycin (p=0.03). These data suggest that for every 10 patients treated with fidaxomicin extendedpulsed dosing versus standard vancomycin dosing, 1 additional patient will achieve clinical cure at 30 days post-treatment. Adverse events occurred at similar rates in the fidaxomicin and vancomycin groups (67% vs. 71%). Fidaxomicin was associated with slightly higher rates of constipation (6% vs. 3%), whereas patients receiving vancomycin had higher rates of other more common adverse events including anemia (3% vs. 6%), cardiac failure (2% vs. 6%), diarrhea (6% vs. 7%), fever (4% vs. 7%), pneumonia (3% vs. 6%), and urinary tract infection (3% vs. 7%). 14 Fidaxomicin extended-pulsed dosing has not yet been directly compared to standard fidaxomicin dosing or a comparable pulsed vancomycin regimen in human subjects. This evidence may be discussed in future CDI guidelines.
5 In addition to the previously mentioned guideline updates, there have also been changes to CDI testing preferences. The IDSA and SHEA recommend that facilities have their own algorithm for molecular tests, along with common antigen and stool toxin tests, instead of immunoassays alone. Pharmacists should continue to diligently monitor antimicrobial stewardship by minimizing the frequency and duration of high-risk antibiotics and the overall number of antibiotics a patient is receiving. While the previous guidelines advised against the use of probiotics in patients with CDI, the updated guidelines provide no recommendation for their use due to insufficient evidence and inconsistency between products. Specific probiotics may be addressed in later guideline updates. Finally, recommendations for pediatric dosing and infection management in this population have also been included in the new guidelines. 4 There have been many updates to the CDI practice guidelines based on evidence published in recent years. Most importantly, first-line therapy recommendations have been updated to recommend the use of vancomycin over metronidazole. In addition to updates addressed in the guidelines, new products such as oral vancomycin solution and bezlotoxumab have been approved which could impact the care of patients with CDI. Pharmacists should be aware of the guideline changes, how it may affect their practices, and be a resource for healthcare providers navigating these updates. 1. Magill SS, Edwards JR, Stat EM, et al. Multistate point-prevalence survey of health care-associated infections. 2014;370: Accessed March 2, Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated infection and of healthcare-associated infection due to methicillin-resistant in community hospitals. 2011;32(4): Accessed March 2, Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA). 2010;31(5): Accessed March 2, McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for infections in adults and children: 2017 updated by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA). 2018;ISSN: Accessed March 2, DOI: /cid/cix Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. 2007; 45: Accessed March 2, Siegfried J, Dubrovskaya Y, Flagiello T, et al. Initial therapy for mild-to-moderate infection. 2016;24(4): Accessed March 2, DOI: /IPC
6 7. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for infection: Results from two multinational, randomized, clinical trials. 2014;59(3): Accessed March 2, Wang S, Xu M, Wang W, et al. Systematic review: Adverse events of fecal microbiota transplantation. 2016;11(8):e Accessed March 5, Bakken JS, Borody T, Brandt LJ, et al. Fecal microbiota transplantation workgroup: Treating infection with fecal microbiota transplantation. 2011; 9: Accessed March 5, Lexicomp. Hudson, OH. Wolters Kluwer Clinical Drug Information; Updated March 3, Accessed March 5, Wilcox MH, Gerding DN, Poxton IA, et al. Bezlotoxumab for prevention of recurrent infection. 2017;376: Accessed March 5, CutisPharma announces FDA approval of FIRVANQ. Wilmington, MA. CutisPharma Accessed March 5, FIRVANQ [package insert]. Wilmington, MA. CutisPharma Accessed March 5, Guery B, Menichetti F, Anttila VJ, et al. Extended-pulsed fidaxomicin versus vancomycin for infection in patients 60 years and older (EXTEND): A randomized, controlled, open-label, phase 3b/4 trial. 2017;18(3): Accessed March 5,
Long-Term Care Updates
Long-Term Care Updates April 2017 Bezlotoxumab to Prevent Recurrent Infection By Amy Wilson, PharmD and Zara Risoldi Cochrane, PharmD, MS, FASCP Introduction The Gram-positive bacteria is a common cause
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationClostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationClostridium difficile (C difficile)
Patient Knowledge and Attitudes About for Clostridium difficile Infection Colin Goodman, MD; Nicholas O Rourke, PharmD; Carla Amundson, MA; and Dimitri Drekonja, MD, MS In a survey of patients with Clostridium
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationLearning Objectives. A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials. Fidaxomicin vs. Vancomycin. Outline 1/3/2012
Learning Objectives A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials Amy E. Lodolce, PharmD, BCPS Assistant Director, Drug Information Group UIC College of Pharmacy Describe the methods and
More informationZinplava. (bezlotoxumab) New Product Slideshow
Zinplava (bezlotoxumab) New Product Slideshow Introduction Brand name: Zinplava Generic name: Bezlotoxumab Pharmacological class: Human IgG1 monoclonal antibody Strength and Formulation: 25mg/mL; solution
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationDrug Class Update with New Drug Evaluation: Medications for Clostridium difficile Infection
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More informationDUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News. Volume 3, Number 6, June 2015
DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News Volume 3, Number 6, June 2015 Diagnostic Testing for Clostridium difficile Infection Background Clostridium difficile
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationOngoing Developments in Management of Clostridium difficile Infection
Ongoing Developments in Management of Clostridium difficile Infection Infectious Diseases Spring Symposium Creighton University School of Medicine April 28, 2018, Omaha, NB Stuart Johnson, MD Loyola U.
More informationDoes Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
ISPUB.COM The Internet Journal of Infectious Diseases Volume 15 Number 1 Does Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
More informationLiterature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationStaphylococcal enterocolitis: Adult Patients (18 years of age and older): 500 mg to 2 g orally in 3 or 4 divided doses for 7 to 10 days. (2.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FIRVANQ safely and effectively. See full prescribing information for FIRVANQ. FIRVANQ (vancomycin
More informationBezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital
Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital Objectives Review pathophysiology, risk factors, prevention, and treatment options of
More informationClostridium Difficile Infection in Adults Treatment and Prevention
Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy
More informationClinical Infectious Diseases Advance Access published December 7, 2012
Clinical Infectious Diseases Advance Access published December 7, 2012 1 Physician Attitudes Towards the Use of Fecal Transplantation for Recurrent Clostridium Difficile Infection in a Large Metropolitan
More informationClostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018
Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile
More informationAtypical Presentation of Clostridium Difficille Infection (CDI).
Article ID: WMC004648 ISSN 2046-1690 Atypical Presentation of Clostridium Difficille Infection (CDI). Peer review status: No Corresponding Author: Dr. Syed A Gardezi, CT1, Medicine,NevillHall Hospital
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZINPLAVA safely and effectively. See full prescribing information for ZINPLAVA. ZINPLAVA (bezlotoxumab)
More informationClostridium difficile Infection (CDI) Guideline Update:
Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH A Webinar for HealthTrust Members Professor of Medicine September 24,
More informationTerapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco
Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationAll POOPed out: fecal microbiota transplant in C. difficile
All POOPed out: fecal microbiota transplant in C. difficile SUSAN M. KELLIE, MD, MPH PROFESSOR OF INTERNAL MEDICINE DIVISION OF INFECTIOUS DISEASES UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE HOSPITAL
More informationFIS 2013, Birmingham
Fidaxomicin: CDDFT Case Studies Dr Deepa Nayar County Durham and Darlington Foundation Trust FIS 2013, Birmingham This meeting has been initiated and funded by Astellas Pharma Ltd. County Durham and Darlington
More informationdeclara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD.
Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. declara&ons No financial disclosures Personal acquaintance, co- worker,
More informationACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,
More informationFecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection
Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection Issue Date: June 2013 Vol. 8 No. 6 Author: Amy Marinski, MSN, RN, CCRN, CNL More than 3 million new cases of Clostridium
More informationC. difficile and ASP Guidelines and Best Practices. Belinda Ostrowsky, MD, MPH, FSHEA, FIDSA February 27 and 28, 2018
C. difficile and ASP Guidelines and Best Practices Belinda Ostrowsky, MD, MPH, FSHEA, FIDSA February 27 and 28, 2018 Disclosure I have no financial disclosures I have made a recent transition from Montefiore
More informationClinical Policy Bulletin: Fecal Bacteriotherapy
Clinical Policy Bulletin: Fecal Bacteriotherapy Number: 0844 Policy Aetna considers fecal bacteriotherapy medically necessary for persons with Clostridium difficile infection, with infection confirmed
More informationClostridium difficile: Can you smell the new updates?
Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize
More informationDuodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience
Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Benoit Guery Unité des Maladies Infectieuses CHRU - Faculté de Médecine Lille Conflicts of interest Conferences,
More informationPatient presentation
Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine
More informationThe Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH
The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick
More informationClostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure
Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma
More informationClostridium difficile Infection (CDI)
18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through
More informationFecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond
Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Amir Patel, MD Assistant Professor of Medicine Froedtert Hospital and the Medical College of Wisconsin I have
More informationFecal microbiota transplantation: The When,the How and the Don t. By Dr Rola Hussein
Fecal microbiota transplantation: The When,the How and the Don t By Dr Rola Hussein Introduction Fecal microbiota transplantation (FMT) involves administration of fecal material containing distal gut microbiota
More informationFlagyl cdiff treatment duration
Flagyl cdiff treatment duration The Borg System is 100 % Flagyl cdiff treatment duration Intracolonic use of vancomycin for treatment of clostridium difficile colitis in a patient with a diverted colon:
More informationUpdate on Clostridium difficile infection.
Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationManaging Clostridium Difficile: An Old Bug With
932 The Red Section see related editorial on page x Managing Clostridium Difficile: An Old Bug With New Tricks Stephen M. Vindigni, MD, MPH 1,2 and Christina M. Surawicz, MD 1 Am J Gastroenterol (2018)
More informationInternational Journal of Food and Allied Sciences
International Journal of Food and Allied Sciences ISSN: 2415-0290 (Print) ISSN: 2413-2543 (Online) DOI:10.21620/ijfaas.2017120-26 Research Article History The Role of Saccharomyces boulardii in the Treatment
More informationCDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers
Disclosures No conflict of interest to declare Acknowledgments Objectives and Agenda Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Guidelines
More informationClinical Policy Title: Fecal transplantation for clostridium difficile infection
Clinical Policy Title: Fecal transplantation for clostridium difficile infection Clinical policy number: 08.02.02 Effective Date: October 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date:
More informationMarch 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments
March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More informationNicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma. L infezione da C difficile grave o complicata
Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma L infezione da C difficile grave o complicata Bagdasarian N et al. JAMA 2015; 313: 398-408 European Society
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationC-ing DIFFiculties in treating recurrent C. difficile infections: the role of pulsed and tapered antibiotic therapy
C-ing DIFFiculties in treating recurrent C. difficile infections: the role of pulsed and tapered antibiotic therapy Pharmacotherapy Rounds Friday, December 7 th, 2018 Jessica Yang, Pharm.D. Post Graduate
More informationPrevention of Cdiff recurrence: Evidence from a Cdiff Antitoxin
Prevention of Cdiff recurrence: Evidence from a Cdiff Antitoxin Prof. Emilio Bouza Departament of Medicine. Hospital Gregorio Marañon and Complutense University. Madrid. Spain Disclosures Last year Participation
More informationC. difficile: When to Do Fecal Microbiota Transplant (FMT)
C. difficile: When to Do Fecal Microbiota Transplant (FMT) Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College
More informationWhat s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington
What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More informationXifaxan. Xifaxan (rifaximin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.34 Subject: Xifaxan Page: 1 of 6 Last Review Date: December 8, 2017 Xifaxan Description Xifaxan (rifaximin)
More informationClostridium difficile in Adults
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2018 ~ Resource #340405 Clostridium difficile in Adults Clostridium difficile (C. difficile)
More informationDisclosure. Objectives. Assessment Questions. History. Clinical Case 2/27/2015. Clostridium difficile update and new therapies
Disclosure Clostridium difficile update and new therapies Corey Frederick, PharmD PGY-2 Pharmacy Resident, Infectious Diseases Jackson Memorial Hospital Miami, Florida I do not have a vested interest in
More informationClostridium difficile Infection (CDI) Guideline
Clostridium difficile Infection (CDI) Guideline Site Applicability All VCH PHC acute care and residential sites. Practice Level Physicians basic skill Pharmacists basic skill Nurses (RN, LPN, RPN) basic
More informationRevisiting Clostridium Difficile Infection
CLINICAL VIGNETTE Revisiting Clostridium Difficile Infection Michael A. Pfeffer, M.D., Ruby Shandilya, M.D., and Jeffrey Hsu, M.Eng. Clostridium difficile infection is commonly seen in patients in the
More informationTreating and Preventing. C. difficile Infections A Review of the Research for Adults
Treating and Preventing C. difficile Infections A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional has said that
More informationClinical Infectious Diseases IDSA GUIDELINE
Clinical Infectious Diseases IDSA GUIDELINE Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and
More information(No Image Selected) Video Submission Confirmation: No Video Upload: Abstract Author: Investigator Commercial Products or Services: No Designed Study:
Found 3 Abstracts CONTROL ID: 1745628 TITLE: Fecal Microbiota Transplantation (FMT) for Treatment of Clostridium difficile Infection (CDI) in Immunocompromised Patients CONTACT (NAME ONLY): Colleen Kelly
More information500,000 29,000. New 2015 Data. Lessa et al, N Eng J Med 2015: 34.2% of CDI cases were considered community-acquired
Cost-effective Treatment of Clostridium difficile Infection in the ICU Kevin W. Garey, PharmD, MS. Professor and Chair University of Houston College of Pharmacy New 2015 Data 500,000 29,000 Lessa et al,
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationStar Articles in Review
Star Articles in Review CDDW/CASL Meeting Toronto, February 10, 2014 Christina M. Surawicz, MD MACG Professor of Medicine Division of Gastroenterology Department of Medicine University of Washington Disclosure
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More informationTreatment of Clostridium Difficile Infection in Community Teaching Hospital: A Retrospective Study
International Journal of Infectious Diseases and Therapy 2018; 3(3): 52-61 http://www.sciencepublishinggroup.com/j/ijidt doi: 10.11648/j.ijidt.20180303.12 ISSN: 2578-9651 (Print); ISSN: 2578-966X (Online)
More informationAnnex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening
Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening There s an updated Annex C Annex C is an extension to the PIDAC Infection Prevention
More informationWhen To Do Fecal Microbiota Transplant (FMT) For C. difficile
When To Do Fecal Microbiota Transplant (FMT) For C. difficile Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College
More informationClinical Review Criteria Fecal Microbial Transplant for Treatment of C. Difficile Infection Fecal GI Infusion Fecal Capsule (G3 OpenBiome)
Clinical Review Criteria Fecal Microbial Transplant for Treatment of C. Difficile Infection Fecal GI Infusion Fecal Capsule (G3 OpenBiome) Criteria Codes Revision History Kaiser Foundation Health Plan
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Fecal Microbiota Transplant MP-066-MD-DE Medical Management Provider Notice Date: 10/15/2018; 04/15/2018 Issue Date: 11/15/2018;
More informationClostridium difficile infections: Drug treatment re-evaluated
Clostridium difficile infections: Drug treatment re-evaluated Kimberly D. Leuthner, PharmD University Medical Center of Southern Nevada August 11, 2016 Random Fact: The human body has 10 13 human cells
More informationNursing Infectious Diseases Topics. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
Nursing Infectious Diseases Topics David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Clostridium difficile Free Access Via Web Source: Cohen SH,
More informationResponders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members)
Infectious Diseases Society of America Emerging Infections Network Report for Query: Recurrent C. difficile Infections (CDI) Overall response rate: 621/1212 (51.2%) physicians responded from 09/26/12 to
More informationAn Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53
An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media formats
More informationmore intense treatments are needed to get rid of the infection.
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Fecal Microbiota Transplant MP-066-MD-PA Medical Management Provider Notice Date: 10/15/2018; 01/15/2018 Issue Date: 11/15/2018;
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More informationThe Bristol Stool Scale and Its Relationship to Clostridium difficile Infection
JCM Accepts, published online ahead of print on 16 July 2014 J. Clin. Microbiol. doi:10.1128/jcm.01303-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 The Bristol Stool Scale
More informationManagement of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery
Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery Rahul Narang, MD Colon and Rectal Surgery Assistant Professor of Surgery No Disclosure Clostridium Difficile Colitis: Treatments,
More informationFollow this and additional works at:
Regis University epublications at Regis University Celebration of Scholarship and Research Center for Scholarship and Research Engagement Spring -11-17 Implementation of education with ongoing feedback
More informationLe infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo
Le infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo Istituto Nazionale per le Malattie Infettive «lazzaro Spallanzani», IRCCS-Roma The infectious cycle of transmission
More informationClostridium difficile
Clostridium difficile Sarah Doernberg, MD, MAS Assistant Professor, University of California, San Francisco Medical Director, Adult Antimicrobial Stewardship Disclosures: Consultant for Actelion, prior
More informationC. DIFF QUIK CHEK COMPLETE. Get the complete diagnostic picture with just one test. TAP HERE TO SEE THE NEXT PAGE
C. DIFF QUIK CHEK COMPLETE Get the complete diagnostic picture with just one test. TAP HERE TO SEE THE PAGE CLINICIAN Would actionable C. difficile test results in less than 30 minutes improve patient
More informationZinplava Swiss Risk Management Plan Summary V1.5. Swiss Summary of the Risk Management Plan (RMP) for. Zinplava. (Bezlotoxumab 1000mg)
Swiss Summary of the Risk Management Plan (RMP) for (Bezlotoxumab 1000mg) Concentrate for solution for infusion Version 1.5 (November 2016) The Risk Management Plan (RMP) is a comprehensive document submitted
More informationADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA
ADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA Candace Marr, DO Catholic Health System University at Buffalo, NY Kevin Shiley, MD Catholic Health System Buffalo, NY FINANCIAL
More informationC. difficile Infection: How it all comes out
C. difficile Infection: How it all comes out Larry Danziger, Pharm.D. Professor of Pharmacy and Medicine College of Pharmacy University of Illinois at Chicago The speaker has no conflicts to disclose.
More informationPage 1 of 10 PRESENTATION ASSESSMENT INTERVENTION. For severe and severe/ complicated disease criteria and treatment, see Page 2
PRESENTATION ASSESSMENT INTERVENTION Patient with 3 unformed stools in last 24 hours 1 Assessment and Management of Has patient been taking laxatives over the past 24-48 hours 2? Stop laxative and reassess
More information